We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.18%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.32B
AUM Growth
+$87.8M
Cap. Flow
+$6.46M
Cap. Flow %
0.49%
Top 10 Hldgs %
27.55%
Holding
138
New
17
Increased
50
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$28.2M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$22.2M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$17.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$17.5M
5
AGN
Allergan plc
AGN
+$10.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38M
2
STJ
St Jude Medical
STJ
+$33.4M
3
TMH
Team Health Holdings Inc
TMH
+$17M
4
ADPT
Adeptus Health Inc
ADPT
+$14.4M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Financials 3.37%
3 Industrials 0.48%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$50.6M 3.84%
162,000
+36,000
+29% +$10.7M
AET
2
DELISTED
Aetna Inc
AET
$44.4M 3.37%
411,000
+25,000
+6% +$2.7M
ACHC icon
3
Acadia Healthcare
ACHC
$2.55B
$42.2M 3.19%
675,000
-137,000
-17% -$8.92M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$36.8M 2.79%
193,000
+21,000
+12% +$3.67M
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$36.8M 2.79%
597,500
+37,500
+7% +$2.37M
GILD icon
6
Gilead Sciences
GILD
$165B
$32.9M 2.49%
325,300
+67,800
+26% +$7.05M
BXLT
7
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$31.6M 2.4%
+810,000
New +$28.2M
PFE icon
8
Pfizer
PFE
$143B
$31.5M 2.38%
1,027,650
+226,610
+28% +$7.13M
HCA icon
9
HCA Healthcare
HCA
$88.4B
$29.1M 2.2%
430,000
-60,500
-12% -$4.22M
COLL icon
10
Collegium Pharmaceutical
COLL
$1.18B
$27.7M 2.1%
1,005,487
+11,087
+1% +$234K
CELG
11
DELISTED
Celgene Corp
CELG
$27.5M 2.09%
230,000
+32,000
+16% +$3.7M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$25.4M 1.92%
560,000
+60,000
+12% +$3.14M
AAAP
13
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$25M 1.9%
+800,000
New +$22.2M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$40.4B
$24.9M 1.89%
379,300
+54,300
+17% +$3.36M
ACRS icon
15
Aclaris Therapeutics
ACRS
$715M
$24.1M 1.83%
+896,154
New +$17.5M
MDCO
16
DELISTED
Medicines Co
MDCO
$23.3M 1.77%
625,000
+30,000
+5% +$1.13M
LLY icon
17
Eli Lilly
LLY
$1.08T
$23.2M 1.76%
275,897
+43,397
+19% +$3.6M
ISRG icon
18
Intuitive Surgical
ISRG
$127B
$21.6M 1.63%
355,500
+31,500
+10% +$1.77M
NBIX icon
19
Neurocrine Biosciences
NBIX
$18.2B
$21.4M 1.62%
377,500
+3,500
+0.9% +$178K
PCRX icon
20
Pacira BioSciences
PCRX
$1.04B
$20M 1.51%
260,000
+92,000
+55% +$5.21M
CI icon
21
Cigna
CI
$78.4B
$17.9M 1.35%
122,000
– –
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$17.5M 1.32%
334,000
+108,000
+48% +$5.16M
PRTA icon
23
Prothena Corp
PRTA
$448M
$16.9M 1.28%
248,000
– –
ELV icon
24
Elevance Health
ELV
$81.5B
$16.8M 1.28%
120,800
+33,300
+38% +$4.59M
WCG
25
DELISTED
Wellcare Health Plans, Inc.
WCG
$16.8M 1.27%
+214,500
New +$17.8M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rock Springs Capital Management held 138 positions worth $1.32B, up 7.1% from $1.23B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q4 2015 filing shows 17 new, 50 increased, 27 reduced and 18 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M. The largest sale was AbbVie, an estimated $38M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 76% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2015 buy was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M.
  • Rock Springs Capital Management added most to Allergan plc in Q4 2015, an estimated $10.7M increase.
  • Rock Springs Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38M.
  • Rock Springs Capital Management fully exited St Jude Medical in Q4 2015, selling an estimated $33.4M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.32B portfolio in Q4 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 18 in Q4 2015.
  • Rock Springs Capital Management's portfolio value rose 7.1% quarter-over-quarter to $1.32B.

Based on Rock Springs Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.